Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Shares Outstanding (2017 - 2025)

Crinetics Pharmaceuticals has reported Shares Outstanding over the past 9 years, most recently at $95.6 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $95.6 million for Q4 2025, up 2.85% from a year ago — trailing twelve months through Dec 2025 was $95.6 million (up 2.85% YoY), and the annual figure for FY2025 was $95.6 million, up 2.85%.
  • Shares Outstanding for Q4 2025 was $95.6 million at Crinetics Pharmaceuticals, up from $94.5 million in the prior quarter.
  • Over the last five years, Shares Outstanding for CRNX hit a ceiling of $95.6 million in Q4 2025 and a floor of $4.8 million in Q1 2022.
  • Median Shares Outstanding over the past 5 years was $60.7 million (2023), compared with a mean of $63.8 million.
  • Biggest five-year swings in Shares Outstanding: surged 11872.92% in 2021 and later tumbled 85.52% in 2022.
  • Crinetics Pharmaceuticals' Shares Outstanding stood at $47.6 million in 2021, then rose by 13.19% to $53.9 million in 2022, then rose by 26.54% to $68.2 million in 2023, then skyrocketed by 36.31% to $92.9 million in 2024, then grew by 2.85% to $95.6 million in 2025.
  • The last three reported values for Shares Outstanding were $95.6 million (Q4 2025), $94.5 million (Q3 2025), and $94.1 million (Q2 2025) per Business Quant data.